New York State Teachers Retirement System Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

New York State Teachers Retirement System acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,283 shares of the biopharmaceutical company’s stock, valued at approximately $1,453,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Alnylam Pharmaceuticals by 5.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after purchasing an additional 130,482 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $18,886,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $29,111,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 1.9 %

ALNY opened at $277.43 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business has a fifty day simple moving average of $274.17 and a 200-day simple moving average of $230.84. The firm has a market cap of $35.78 billion, a P/E ratio of -105.89 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period last year, the business earned $1.15 EPS. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALNY. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. JPMorgan Chase & Co. lifted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Barclays increased their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 4th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $294.50.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.